Feb. 26 at 5:14 AM
$IOVA
Shorts loaded up hard—short interest spiked to 131 million shares (~38-47% of float, 14+ days to cover). To cover comfortably on the downside without getting wrecked, they'd need a massive negative PR bomb to unleash heavy selling volume and crash the price.
Reality check: Iovance's stacked catalysts are lined up to drive the stock higher—incoming catalysts: revenue forecast, Canadian revenues, lung cancer Fast Track progress, upcoming trial readouts IOV-40001, Endo. Shorts will likely be forced to cover at much higher levels instead.
Institutional ownership has climbed sharply (now 59-73%+ across sources), yanking more shares out of the float and tightening supply even further. With the float locked up and upside catalysts flowing, this setup screams potential squeeze pressure if positive news hits. Shorts beware—higher prices incoming.
